EZH2 and chronic myelogenous leukemia, BCR-ABL1 positive: At the point of CML diagnosis the mutation was found at only 1% VAF, indicating that the EZH2-positive clone was likely suppressed by Ph-positive cells and unmasked during TKI therapy [33].